Justin Noznesky Sells 6,182 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Justin Noznesky sold 6,182 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total value of $239,861.60. Following the completion of the transaction, the insider directly owned 100,219 shares in the company, valued at approximately $3,888,497.20. This trade represents a 5.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

AtriCure Stock Down 6.0%

Shares of AtriCure stock opened at $37.76 on Friday. The company has a quick ratio of 3.18, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $43.18. The business has a fifty day simple moving average of $31.10 and a 200 day simple moving average of $31.34. The stock has a market cap of $1.92 billion, a PE ratio of 179.82 and a beta of 1.24.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the prior year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts predict that AtriCure, Inc. will post 0.2 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on ATRC. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday. Raymond James Financial set a $52.00 target price on shares of AtriCure in a research note on Tuesday, July 21st. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Finally, Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

Hedge Funds Weigh In On AtriCure

Several institutional investors have recently modified their holdings of ATRC. AQR Capital Management LLC grew its position in shares of AtriCure by 1.0% in the 1st quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after purchasing an additional 837 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in AtriCure by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after buying an additional 1,230 shares during the period. Goldman Sachs Group Inc. raised its holdings in AtriCure by 1.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after buying an additional 8,956 shares during the period. Jane Street Group LLC lifted its stake in AtriCure by 658.3% in the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock valued at $3,254,000 after buying an additional 87,553 shares in the last quarter. Finally, Strs Ohio bought a new position in AtriCure in the first quarter valued at approximately $158,000. Institutional investors own 99.11% of the company’s stock.

Key AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure’s recent second-quarter results exceeded expectations, with earnings per share of $0.18 versus the $0.13 analyst estimate and revenue of $153.6 million versus $151.8 million expected. The company also improved from a year-ago loss, supporting its growth and profitability outlook. AtriCure second-quarter results presentation
• Positive Sentiment: UBS lowered its price target from $55 to $50 but retained a Buy rating. The revised target still indicates meaningful potential upside and suggests the analyst remains constructive on AtriCure’s medical-device business. UBS AtriCure price target report
• Neutral Sentiment: Options-market coverage points to the possibility of a significant upcoming move in ATRC, but the available information does not establish whether traders are positioning for a rise or decline. Elevated options activity could contribute to short-term volatility. AtriCure options activity article
• Neutral Sentiment: New share-registration filings may give AtriCure additional financing flexibility. However, investors may monitor the filings for potential future share issuance and dilution. AtriCure share registration article
• Negative Sentiment: Insiders sold approximately $1.42 million of AtriCure shares. Director Sven Wehrwein reduced his position by about 38%, while insiders Justin J. Noznesky and Vinayak Doraiswamy each sold roughly 6% of their holdings. The clustered selling may weigh on sentiment, particularly after ATRC’s strong advance toward its 52-week high. AtriCure insider selling report

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.